Lipocine announces financial results for the third quarter ended september 30, 2023

Salt lake city , nov. 8, 2023 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company focused on treating central nervous system (cns) disorders by leveraging its proprietary platform to develop differentiated products, today announced financial results for the third quarter and nine months ended september 30, 2023, and provided a corporate update. clinical program highlights neuroactive steroids on october 18, lipocine completed a successful meeting with the fda on lpcn 1154, which is in development for postpartum depression (ppd).
LPCN Ratings Summary
LPCN Quant Ranking